Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Vista Pharmaceuticals's Gross Margin % or its related term are showing as below:
BOM:524711'
s Gross Margin % Range Over the Past 10 Years
Min: -195.38 Med: 14.15 Max: 42.09
Current: 3.29
During the past 13 years, the highestGross Margin % of Vista Pharmaceuticals was 42.09%. The lowest was -195.38%. And the median was 14.15%.
BOM:524711's Gross Margin % is ranked worse than 97.87% of 941
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:524711: 3.29
Vista Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Vista Pharmaceuticals was 0.00% per year.
Vista Pharmaceuticals (BOM:524711) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Vista Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Vista Pharmaceuticals Gross Margin % Related Terms
Vista Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Vista Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524711 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vista Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vista Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vista Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Vista Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Vista Pharmaceuticals (BOM:524711) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Vista Pharmaceuticals and its competitors. According to the industry distribution chart, Vista Pharmaceuticals ranks #921 out of 941 companies in the Drug Manufacturers industry, placing it in the top 97.9%.
Is Vista Pharmaceuticals' Gross Margin % too high?
Vista Pharmaceuticals' current Gross Margin % is 0.00%. Based on the distribution chart, Vista Pharmaceuticals ranks #921 out of 941 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vista Pharmaceuticals has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vista Pharmaceuticals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vista Pharmaceuticals ranks #921 out of 941 companies for Gross Margin %. This places Vista Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 48.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Vista Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vista Pharmaceuticals's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vista Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vista Pharmaceuticals (BOM:524711) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6.08, compared to a current price of ₹7.08 — trading 16.4% above its estimated fair value. The current Gross Margin % is 0.00%. Vista Pharmaceuticals' overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Vista Pharmaceuticals (BOM:524711), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vista Pharmaceuticals (BOM:524711) Overvalued in 2026?
Based on GuruFocus' analysis, Vista Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹7.08 is trading 16.4% above its estimated GF Value™ of ₹6.08.
GuruFocus considers Vista Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for BOM:524711:
Gross Margin %: 0.00%
GF Value™: ₹6.08 vs. price of ₹7.08 (16.4% above fair value)
No single metric tells the full story. See the BOM:524711 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vista Pharmaceuticals Ltd is an Indian company engaged in a single operating segment, which is the manufacturing of Pharmaceutical products. The company offers over-the-counter and prescription generic drug products such as tablets, capsules, and liquids covering various therapeutic categories. Some of the drugs in tablet dosage forms are Sulfamethoxazole and Trimethoprim, Bismuth Subgallate, Pyrantel Pamoate, Aspirin, Ibuprofen, Ranitidine HCl, and others. Nifedipine, Piroxicam, and Indomethacin are the drugs offered by the company in a capsule dosage form. The company generates all of its operating revenue from sales within its domestic market.
47GF Score
Get the complete analysis for BOM:524711
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524711 has been successfully added to your 
